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A B S T R A C T
Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration
(FDA) suggests a positive trend in current research and development (R&D) output. Prior to this, the
cost of each NTE was considered to be rising exponentially, with compound failure occurring mainly in
clinical phases. Quantitative systems pharmacology (QSP) modelling, as an additional tool in the drug
discovery arsenal, aims to further reduce NTE costs and improve drug development success. Through in
silico mathematical modelling, QSP can simulate drug activity as perturbations in biological systems and
thus understand the fundamental interactions which drive disease pathology, compound pharmacology
and patient response. Here we review QSP, pharmacometrics and systems biology models with respect to
the diseases covered as well as their clinical relevance and applications. Overall, the majority of modelling
focus was aligned with the priority of drug-discovery and clinical trials. However, a few clinically impor-
tant disease categories, such as Immune System Diseases and Respiratory Tract Diseases, were poorly covered
by computational models. This suggests a possible disconnect between clinical and modelling agendas. As a
standard element of the drug discovery pipeline the uptake of QSP might help to increase the eﬃciency of
drug development across all therapeutic indications.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
1. Introduction
1.1. The price of productivity
At the turn of the 21st century, a prevalent view of the pharma-
ceutical industry productivity was that compound attrition through-
out the drug discovery pipeline was increasing [1, 2] and that the
annual output of new therapeutic entities (NTEs) was in decline [3].
A broader picture, on the other hand, implies that there had been
a tenuous growth in number of annual NTEs approved since 1940
(Fig. 1). NTEs are novel chemical and biological drugs where the
active moiety has not previously been approved by the FDA. As a
result, they are often used as a measure of pharmaceutical research
and development (R&D) output [4]. Despite the apparent decline in
NTEs seen over the last two decades, the long-term growth in NTE
output appears to be unabated (Fig. 1). The primary concern within
the pharmaceutical industry is that dramatic increases were seen
in the total cost of bringing each NTE to market [5, 6]; the cost of
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drug discovery was seen to increase exponentially [7]. However, the
evidence suggests here as well that the cost per NTE might have
reached a plateau by 2010 following the rise in approvals and may
have even been in decline since [8, 9] (Fig. 2). In lieu of this perceived
negative trend, there could be instead a positive shift in raw R&D
output in the pharmaceutical industry.
The rapidly rising cost of drug discovery may have been, in
part, caused by the increasing frequency of compound termination
in the highly expensive clinical research phases. Although the
cost per NTE may be decreasing (Fig. 2), the contribution of late-
stage drug failure to pharmaceutical expenses remains substantial.
Drug attrition which occurs during clinical trials stages is caused
by unfavourable eﬃcacy, lack of commercial viability and poor
safety [10, 11]. To effectively combat this costly termination of
drugs, the pharmaceutical industry has been keen to augment the
drug discovery process with theoretical and computational mod-
elling [12–18]. Models offer cheap predictive solutions for drug phar-
macokinetics (PK), pharmacodynamics (PD) and patient population
responses. Models are also capable of providing novel insights into
fundamental biologywhich furthers our understanding of nature and
diseases [19, 20].
http://dx.doi.org/10.1016/j.csbj.2016.09.002
2001-0370/ © 2016 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Total new therapeutic entity (NTE) approvals since 1938. New data since 2008
illustrates the recent positive shift in NTE output. The number of NTEs approved in
2014 and 2015 is surpassed only by 1996 when a backlog of new drug applications
(NDAs) may have been rapidly processed following a change in regulations. Data was
sourced from the Food and Drug Administration (FDA).
1.2. Pharmacokinetics, pharmacodynamics and pharmacometrics.
The models by Teorell [21, 22] are often regarded as the founda-
tions of mathematical modelling in pharmacology [23]. PKmodelling
is largely focused on the absorption, distribution, metabolism and
excretion (ADME) properties of compounds, i.e. what the body does
to the drugs. It was not until the 1950s that the intrinsic drug activity
or pharmacodynamics (PD), i.e. what the drug does to the body, was
effectively considered in modelling. To understand and predict the
complete effect of drug administration, both elements were com-
bined as PK/PD models [24]. The ﬁrst dedicated pharmacokinetics
software, NONLIN, began distribution in 1969 and signalled the start
of a busy period for PK/PD modelling. Multiple advancements in
techniques and programs over two decades caught the interest of the
FDA who then encouraged the use of quantitative modelling in drug
development [25]. At this time, and possibly resulting from this sud-
den interest, kinetics-mediated drug attrition in clinical phases was
dramatically reduced [10]. Traditional pharmacokinetics, pharmaco-
dynamics and statistical pharmacometric models, based on empir-
ical or semi-mechanistic representations, have more recently been
complemented by physiologically-based pharmacokinetic (PBPK)
models, using more accurate representations of the various body
compartments. PBPK models incorporate drug-independent data
such as tissue blood ﬂow,which enables inter-compound predictions
and inter-species translation [26, 27].
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Fig. 2. The price of drug development from 1980 to 2014. An exponential increase
in new therapeutic entity (NTE) cost is seen before 2008. The cost was calculated
using R&D expenditures data given by PhRMA member companies [8] and annual
Food and Drug Administration (FDA) reports on NTE approvals seen in Fig. 1. It is
assumed that the given PhRMA members’ expenditure proportionally represents the
global expenditure over time and that these were adjusted for inﬂation.
Pharmacometric models are designed to predict the biological
variability in patient populations which can be used to predict clin-
ical trial outcomes. Lee et al. studied the success of pharmacological
models in FDA approval decisions between 2000 and 2008 [28]. They
show a six-fold increase in pharmacometric analyses over the nine
years and suggest that the pharmacometric elements were essential
for approval in themajority of NDAs [28–30].The PK/PD success story
in preclinical prediction and the continued value of pharmacometrics
in clinical stages suggests that more sophisticated and mechanistic
pharmacological modelling approaches may help to further reduce
the current sources of late-stage attrition.
1.3. Mechanistic modelling with systems biology
For the better part of a century, computational modelling and
simulation approaches have been essential in understanding biology.
Simple simulations of biological systems as early as the giant squid
axon model by Hodgkin and Huxley in 1952 [31] illustrate that the
integration of such models with experiments can reveal novel emer-
gent properties. The added value of computational models in driving
hypotheses has then led to the generation of a separate ﬁeld of
study in its own right, systems biology. Heralded as one solution to
understanding the ‘data explosion’ [32], the ﬁeld has been embraced
globally. Systems biology is the interpretation and study of biologi-
cal networks as a holistic approach. The rationale is that the dynamic
response of a whole system, such as the human body, to a stimulus
is governed by the collective individual responses of all components
of the system. Computational models are then necessary in systems
biology because of the complex and multifaceted interactions which
can be readily described by mathematical models but do not lend
themselves to intuitive understanding.
In discussing the elements of systems biology, Kitano [33] points
out that, to fully understand biology at a system-level, one needs
to determine the structure of the system. This encompasses the
biochemical and physical entities in a network of interactions. Fur-
thermore, the level of understanding also requires knowledge of
the time-dependent network interconnectivity. A simple deﬁnition
has therefore been proposed for systems biology models using the
following criteria [34]: A functional model must contain
1. The components that constitute the biological system of
interest.
2. The temporal dynamic nature of each individual component of
this system.
3. The interconnectivity and temporal dynamic interaction
between these components.
Quantitative systems pharmacology (QSP) draws its inspiration
from the need for biologically mechanistic modelling, the success of
pharmacometrics modelling and systems biology.
1.4. Quantitative systems pharmacology
Aiming to incorporate detailed biological processes within PK/PD
and PBPK, QSP is the application of systems biology modelling
to drug discovery. A working deﬁnition was provided initially by
Allerheiligen in 2010 [35] and extensively by Sorger et al. in an
NIH white paper in 2011 [36]. In brief, QSP is focused on the drug-
gability of targets within biological systems. It relies on dynamic
mathematical and computational analyses which integrate multiple
experimental data and, similar to systems biology, QSP models are
concerned with the emergent properties found in detailed repre-
sentations of biological systems. Furthermore, the output of QSP is
a knowledge-base or model with predictive capabilities to enhance
drug discovery. With this summary in mind, an additional criterion
can be appended to the systems biology model description [34] to
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deﬁne QSP. A quantitative systems pharmacology model should also
include
4. The modulation of components and dynamic interactions by
putative therapy or compound(s).
In practice, this already appears to be a key aspect of the majority
of systems biology analyses. However, this is the principal rationale
behind the task of constructing a QSP model. Given the criteria pre-
sented here, the construction of a QSP model is reliant upon the
existence of quantitative temporal data. This reliance has been a lim-
iting factor for the development and use of mechanistic modelling in
drug development in the past. Lately however, the accumulation of
relevant data has enabled a reasonable use of QSP models, at least in
basic and preclinical research. Thematch was struck in a white paper
published in 2011 [36]. Following this, the quantity of published arti-
cles describing systems pharmacology models, as well as reviews of
their utility, has grown substantially. As shown in Fig. 3, although
the term systems pharmacologymade a notable appearance in papers
from 2010, a 9-fold increase was seen between 2011 and 2013 with
9 to 82 articles published in each year respectively.
This increased interest may indicate that the pharmaceutical
industry is beginning to integrate systems-level modelling as a
standard element of the drug discovery pipeline. Nonetheless, the
mainstream application of QSP modelling and the bringing of mod-
elling into the clinical stages of drug development still requires
further effort. QSP modelling has to effectively address the clinical
requirements, such as descriptions of statistical patient variability
or long-term disease progression, and improve the accessibility of
modelling for clinicians and pharmaceutical companies [37]. Further
work in perfecting QSP modelling is needed for meeting all expecta-
tions. From target identiﬁcation through to approval, QSP is proposed
as the required tool in continuous program evaluation for predict-
ing and minimising the high cost of late-stage drug attrition [35].
How has the mantle been upheld so far? Recent reviews have dis-
cussed the potential goals, methods and application of QSP [38–41].
The present mini-review is a brief attempt to examine the current
scope and extent of the QSP modelling ﬁeld.
2. The scope of QSP models
A short examination makes clear that a simple search query, such
as that performed in Fig. 3, is not capable of truly retrieving all QSP
models in literature. Such an attempt frequently returns reviews
and static network analyses but often fails to capture research
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Fig. 3. The rise of publications in Systems Pharmacology. A simple search query in
Pubmed was used to return all articles explicitly containing “systems pharmacology”
in the title, abstract or key words sections (n = 352). Not all abstracts refer to systems
pharmacology models. The expected number of articles published in 2016 (*) is a
simple prediction based on the number of articles currently available in 2016 (72 ×
(12/7)). Performed on the 15th of July 2016.
which can otherwise, given the criteria in 1.3–1.4, be described as
systems pharmacology modelling. It is also unrealistic to expect
“systems pharmacology” or “QSP” to appear explicitly in the more
dated research abstracts. In fact, we can see that the term “systems
pharmacology” was not mentioned in Pubmed until 2004 (Fig. 3).
Therefore, in an effort to capture the spread of QSP modelling across
therapeutic areas and indications, we constructed a more complex,
wider andmore precise, textmining query to recall relevant research
abstracts fromMedline dated from 1965 to 2015. The query included
a large set of positive key terms including, amongst others, systems
pharmacology and mathematical model (The full text mining analysis
will be presented in a more detailed manner in a separate research
paper). Initially, a set of negative terms were also included. How-
ever these substantially decreased the recall of the positive control
and reduced the total number of modelling abstracts retrieved. The
abstracts and clinical studies for this time period were annotated
withMedical Subject Headings (MeSH) 2014 and categorised into the
separate disease branches.
The result of this analysis shows that while generally matching
the agenda of clinical trials, in a few disease categories, the focus
of modelling literature is poorly aligned with clinical interest. For
example, Fig. 4 shows that the fractions of documents discussing
Immune System Diseases, Respiratory Tract Diseases and Digestive
System Diseases were approximately two-fold greater in clinical
studies than in the modelling literature. Therefore, certain diseases
may lack an extensive modelling arsenal. Conversely, categories
such as Bacterial Infections and Mycoses or Congenital, Hereditary, and
Neonatal Diseases and Abnormalitieswere commonplace in modelling
literature but were comparatively much less prevalent in clinical
trials. Unsurprisingly, there appeared to be little clinical interest in
Animal Diseases (Fig. 4).
The BioModels database was included in this assessment as
a positive control for dynamic biological models since it is the
largest public repository of curated mathematical models in systems
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Stomatognathic Diseases
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Substance−Related Disorders
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Fig. 4. Clinical trials and modelling. Clinical studies, modelling literature and positive
control abstracts were labelled with diseases by their in-text occurrence. Each disease
was categorised under MeSH 2014 disease branches and documents without any
disease were omitted. The fraction of documents labelled with each disease was cal-
culated using the nd for each corpora (Table 1). The software I2E© 4.2 (Linguamatics)
was used to run the query and perform the MeSH term extraction.
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biology [42, 43]. The query retrieved 76% of all abstracts with models
stored in BioModels. However, only 35% of the models stored in
BioModels were labelled with a disease term (Table 1). Note that
a given document could be tagged for multiple disease categories.
One caveat of this data set is that it may not be enriched for
criterion 4 in deﬁning a QSP model. Whereas the image resulting
from the text mining analysis may not portray the full scope of
QSP or pharmacological modelling, the fraction of positive control
articles retrieved suggests that the recall of models by the query
was reasonable. However, samples indicate that, whilst 18% of total
Medline abstracts were systems modelling papers, only 5% of the
total abstracts retrieved were pharmacological models.
The current approach made no distinction between QSP and
PK/PD or pharmacometrics models and, as the majority of retrieved
documents were not systems biology or pharmacology, a poor over-
all precisionwas expected. Since this study only considered abstracts
available in Medline, it did not take into account unpublished in-
housemodelling works and publishedmaterials not indexed inMed-
line. Moreover, explicit textual references to a disease were required
for a document to be categorised within MeSH disease branches.
Therefore, high-resolution models that mentioned speciﬁc genes,
proteins or pathwayswithout explicitlymentioning the diseasewere
missed. Finally, other errors may lie within the classiﬁcation itself.
The MeSH branch Pathological Conditions, Signs and Symptoms was
omitted due to its ambiguous nature. Annotation of MeSH terms
can be inconsistent or false and some diseases, often tissue-speciﬁc
cancers, fall into multiple categories. Clearly the current analysis can
be improved on the side of precision.
All that said, with a few exceptions, the spread of diseases covered
by BioModels broadly spanned the spectrum of models mentioned
in Medline. A concerted effort within the BioModels database has
focused on models of diabetes [44]. This may explain why the focus
of Nutritional and Metabolic Diseases or Endocrine System Diseases in
clinical studies is closer to that of the BioModels database than the
overall modelling literature (Fig. 4).
3. The extent of QSP models
The consistent application of computational modelling analyses
in NDA success is clear evidence for the beneﬁcial application of the-
oretical models in drug discovery [29]. QSP models also provide a
method to further understand the biological mechanisms and pre-
dict the ideal targets, drug dose and toxicological properties. This
improves the conﬁdence in drug eﬃcacy and safety proﬁles prior
to success of an NDA. One particular and compelling use case of
QSP modelling is the application of a calcium homeostasis model by
Peterson and Riggs [45][BioModels Database: MODEL1604270004].
Khurana et al. adapted a publicly accessible version of the model
speciﬁcally for the FDA review of a Biologics License Application in
2014 [46]. This model was then used to explore the kinetics and
drug administration of a recombinant human parathyroid hormone.
Table 1
The three corpora used in this analysis. Due to technical limitations,
fewer documents were labelled with diseases (nd) than the total
number of documents in each corpus (nt).
Corpus nt nd
Clinical studiesa 177,609 147,235
Modelling literatureb 215,097 85,676
Positive control literaturec 687 244
nt total number of documents; nd number of documents labelled
with a disease.
a clinicaltrials.gov.
b Medline — text mining query for models.
c BioModels database.
Simulations demonstrated that the dose regimens or drug properties
could be optimised to provide a better adherence to the therapeutic
window. In fact, a clinical study has been ﬁled this year following the
conclusions drawn from the QSP dose optimisation.
Below, we present several other example cases illustrating the
application and utility of QSP models in diseases of clinical priority.
3.1. Neoplasms
Neoplasms were labelled in 27% of clinical studies, conﬁrming
that oncology is highest on the clinical agenda (Fig. 4). QSP has
analysed the spatio-temporal dynamics of tumours with models of
tumour growth, drug delivery and intervention eﬃcacy [47, 48].
For instance, the QSP model by Sharan and Woo [49] [BioModels:
MODEL1604270003] integrated aspects of growth, signalling and
biomarkers. The model explored treatment with the anti-vascular
endothelial growth factor (VEGF) agent sunitinib. A further mod-
elling exercise combined the mechanistic signalling module with
additional clinical responses [50]. This highlighted the beneﬁts of
effective biomarker monitoring and dose optimisation in complex
cancer therapy. Preclinical analyses of drug combinations is one
application of modelling efforts in cancer. A model by Zhu et al. [51]
[BioModels: MODEL1604270000, MODEL1604270001] assessed the
dose patterns of two anti-pancreatic cancer molecules, gemcitabine
and birinapant in cell culture. Although the model was not further
translated to an organismal scale, it illustrated how preclinical mod-
elling can shortlist optimal dose schedules for clinical trials in
contrast to current regimens [52].
3.2. Nervous system diseases
Drug development in central nervous system (CNS) diseases such
as Alzheimer’s disease has been plagued by poor translation of eﬃ-
cacy from animal models into humans [53, 54]. Low predictive
precision in animal models is often caused by signiﬁcant differences
in neuronal circuitry between species as well as unknown CNS biol-
ogy and disease pathology. Using mathematical interpretations of
the known processes, systems modelling is capable of testing mul-
tiple hypotheses to predict the possible mechanisms of drug action.
The quantiﬁable nature of this approach is also ideal as a transla-
tional step or compliment to animal models [55]. For example, by
humanising parameters derived from animal models in a dynamic
network, it may be possible to predict the outcome of an interven-
tion in humans before clinical trial commencement. This further be
used to specify the compound properties, if any, required for drug
success in humans where a compound may not appear to be eﬃca-
cious. Low patient eﬃcacy in clinical trials of drugs for CNS diseases
means that early indication of clinical effect, or lack thereof, is highly
important in decisionmaking. For instance, Nicholas et al. [56] devel-
oped a QSP model to evaluate the potential of 5-HT4 receptors as a
target to treat Alzheimer’s disease. They coupled a simple cortical
neuron model with a ligand competition module for 5-HT4 receptor
binding. The model demonstrated that low eﬃcacy 5-HT4R agonists
would worsen the disease state when assessing the clinical out-
come of a serotonergic agonist in scopolamine-induced cognitive
deﬁcit patients. It was shown that a threshold intrinsic activity of the
agonist-receptor complex was necessary to modulate the pathway
for improvements on patient cognition.
Roberts et al. [57] developed a similarly structured model with
the NEURON software and used a QSP approach to study the atten-
uation of parkinsonian hypokinetic motor symptoms. The model
integrates the neuronal circuitry of the cortico-striatal-thalamic loop
with ligand-receptor competition dynamics. The local ﬁeld potential
of the subthalamic nuclei was used as a clinical marker. Calibrated
using the polypharmacology of 43 anti-psychotic drug combinations,
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the clinical outcomes of dopamine, NMDA, adenosine, 5-HT modu-
lators and even placebo treatments were predicted in simulations.
This method quantiﬁed which targets could generate the optimal
response and which compounds offered the greatest therapeutic
potential. When directly parametrisedwith human data, simple neu-
ronal circuitry models mitigate the problems arising from species
translation.
3.3. Cardiovascular diseases
Mechanistic models have greatly contributed to the fundamental
understanding of cardiovascular diseases from signalling [58] to ﬂuid
dynamics [59]. In therapeutics, models of drug-eluting arterial stents
have been used to explore the mechanisms and increase eﬃciency of
stent development [60]. Garmaroudi et al. [61] presented a combi-
natorial approach to pathway perturbation in cardiovascular disease
signalling. They used QSP modelling to evaluate options of polyphar-
macology in minimising adverse reactions and countering biological
redundancy; systems modelling enabled researchers to examine
the network-wide effects of multi-target perturbations. The model
assessed the ability of several compounds to restore impaired nitric
oxide-cyclic guanosine 3′,5′-monophosphate (NO• -cGMP) signalling.
The authors simulated the dynamic elevation of cGMP resulting from
377 different individual, double or triple parameter perturbation
combinations. One optimal triple reaction perturbation was pre-
dicted to increase cGMP substantially beyond all other combinations.
The predictions were then validated in vitro using clinically available
compounds.
Cardiotoxicity is associated with cardiovascular diseases, and an
important hurdle in drug discovery. Individual drugs and drug–drug
interactions can stimulate cardiovascular arrhythmia as an adverse
reaction. Computational modelling efforts have been launched to
deﬁne the mechanisms underlying the effects of a multitude of com-
pounds on arrhythmic events as well as their therapeutic windows
for a multitude of compounds [62]. In forming QSP models, the in sil-
ico reconstruction of known cardiac biology could be combined with
the observed clinical outcomes to predict drug-mediated cardiovas-
cular diseases. For example, a PBPKmodel combined with a response
model of cardiomyocyte ion-channels [63] was used to predict the
drug–drug interaction of domperidone and ketoconazole on QT pro-
longation. These cardiovascular disease examples demonstrate that
QSPmodelling can explore the promising prospects of polypharmacy
in drug-discovery [64].
3.4. Nutritional and metabolic diseases
The global incidence of nutritional and metabolic diseases such
as diabetes is steadily rising. Clinical efforts to understand and treat
diabetes have been mirrored by a large plethora of models com-
prehensively summarised by Ajmera et al. [44]. The scales of these
models range from intracellular signalling to systemic homeostasis
and disease progression. One recent QSP model explored the current
assumptions underlying the therapeutic mechanism of interleukin-
1b (IL-1b) blockade in type-2 diabetes mellitus (T2DM) [65]
[BioModels: MODEL1604 270002]. The authors described a QSP dis-
ease progression model of T2DM including a model of b-cell func-
tion. The simulation of therapeutic perturbations explored the facets
of anakinra treatment. The model predicted that improved b-cell
function is responsible for its short-term eﬃcacy. Additionally, pre-
dictions estimated that a persistent improvement in disease state
was governed by an increased b-cell mass but only after sustained
therapy. They concluded that (IL-1b) suppression over several years
may be required to reach a signiﬁcant therapeutic endpoint.
3.5. Diseases with nascent QSP
Contrary to cancer, CNS and cardiovascular diseases, several
disease categories have rarely been studied using computational
modelling. However, the situation is changing in a few cases.
A recent platformwas designed to simulate the systemic immune
response to pathological disruptions. The fully-integrated immune
response model (FIRM) describes the effects of several cytokines
upon a variety of cell types [66] [BioModels: BIOMD0000000608].
The application of FIRM was demonstrated on tuberculosis, tumour
rejection and pathogen response. Adoption of FIRM as a QSP environ-
ment could prove useful in predicting the risk of compromising the
immune system by compoundswith immunosuppressive properties.
Substantial clinical interest in respiratory tract diseases has
encouraged the construction of a QSP model for exploring the mech-
anisms underlying the effects of a 5-lipoxygenase inhibitor, Zileuton,
on asthma [67] [BioModels: BIOMD0000000490]. Themodel explores
target comparison, proposes an emergent explanation for clinical
data and discusses optimal dose strategies.
In the gastrointestinal system, modelling the interaction between
gut and drugs is obviously key to optimising drug oral administra-
tion. However, only a very small fraction of QSP research focuses on
diseases of the digestive systems (note that we are only talking about
QSP models, agent-based models typically use the gut epithelium as
the tissue of choice [68]). Modelling intestinal C. diﬃcile infection,
Leber et al. generated a model exploring the immune response of the
gut [69] [BioModels: BIOMD0000000583]. The model predicts that
suppression of the gut immune response may, counter-intuitively,
aid recovery from infection and perhaps assist in fecal transplant
therapy. Expansion of QSP studies into sparsely modelled (but oth-
erwise clinically important) diseases may provide ways to reduce
late-stage attrition. The ease at which modelling can be performed
will be crucial to achieve this expansion.
4. Modelling is easy these days
Common modelling approaches used in systems biology can be
easily applied to QSP, and many tools are available for the curious
researcher [70, 71]. For example, data obtained from open-access
databases of biological networks such as KEGG Pathways [72] or
Reactome [73] can be used with programs like Cytoscape [74]
and CellDesigner [75]. To describe a dynamic system, mathe-
matical equations can be deﬁned and solved in a wide variety
of freely available environments such as Copasi [76], R [77] or
Octave [78]. Proprietary environments such as SimBiology® (part of
MATLAB
®
[79]) are also often used for model development. Finally,
some commercial drug development programs specialise in pre-
dicting the ADME properties of compounds, like Simcyp [80] or
Gastroplus™.
A typical modelling work ﬂow relies on several software tools
and the communication between tasks or between researchers must
be seamless. As mentioned by Leil and Ermakov [81], the lack of
acceptable standards and tools could hinder the emergence and com-
monplace use of QSP in drug discovery. Standardisation efforts facil-
itate model sharing, reproducibility of their analysis and ultimately
domain repute and progression. In systems biology the Systems
Biology Markup Language (SBML) [82] has been a de facto standard
for more than a decade. Developed by the community, it is supported
by hundreds of software tools, databases and modelling platforms.
The pharmacometrics community recently developed the Pharma-
cometrics Markup Language (PharmML) [83]. PharmML was devel-
oped through the DDMoRe consortium [84], a partnership between
academic partners and the pharmaceutical industry. It was designed
as a common format or lingua franca between a large variety of
popular pharmacometrics tools and aims at establishing a standard
language for PK/PD and QSP modelling. Common formats such as
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PharmML and SBML encourage the sharing of models, fuelling sci-
entiﬁc collaboration. This also promotes model progression, reuse
and much needed training of new translational scientists in both
academia and industry.
The DDMoRe project also aims to create and improve open soft-
ware resources available for modelling in drug development. For
instance, it provides a freely available repository for sharing phar-
macological models (http://repository.ddmore.eu/). BioModels [42]
itself provides an increasing number of curated pharmacological
models, including PK/PD models (the models mentioned in this
review are freely available in BioModels). Placing models in open-
access repositories increases their visibility and the availability of
their code allows them to be reused. This is of great importance as it
may help to concentrate computational efforts and provide clinically
relevant models to researchers.
5. Summary and outlook
The number of systems pharmacology articles published has
increased dramatically since 2011 bringing an array of quantitative
models (Fig. 3). These models are capable of capturing dynamic
systems at varying scales, simulating the purported effect of drugs
and strategies used in clinic, and assessing the validity of our current
biological understanding and clinical outcomes. Here we have brieﬂy
discussed examples of the application and extent of current QSP
modelling, in particular for disease categories rich with models. A
preliminary evaluation of the disease focus suggests that the efforts
of modelling could be align better with the clinic.
Both Cardiovascular diseases and Nervous systems diseases are
prone to frequent compound failure [12]. In these complex disease
categories, high drug attrition rates may partially explain the
popularity of seeking a modelling approach. A traditionally large
modelling effort is, however, not the assurance of success. While
Neoplasms is the most popular disease category for modelling, oncol-
ogy has the highest compound failure rate in phase II and III trials [10,
12, 85]. An explanation could be the large number of post-mortem
models, built following terminated clinical trials. Whilst these are
useful in both model validation and for identifying the causes of ter-
mination, failure of the compounds may have been foreseen by the
earlier use of modelling.
In a follow-up review on the FDA’s application of the calcium
homeostasis model [45, 46], Peterson and Riggs suggested that the
QSP modelling ﬁeld will be emboldened by milestone cases such
as the Natpara® BLA in 2014 [39]. However, they also stressed
that several regulatory factors impede a sudden embrace of QSP
models in the pharmaceutical domain. Notably, the proper educa-
tion and training of future QSP scientists is an important prerequisite
for industrial interest, as discussed in detail by Sorger et al. [36].
Paramount however, and governing the rate at which QSP is adopted,
is the frequency at which key models are successfully put to the
test. The accumulation of positive use cases may encourage a shift
towards the much needed earlier applications of modelling in the
drug development pipeline.
Community-wide interest in QSP is nevertheless increasing. Fol-
lowing the two NIH QSP workshops in 2008 and 2010, reviews
have been published annually which offer in-depth discussions on
the range of applications, examples and insights offered by QSP
modelling [38, 40, 81, 86-89]. A UK Quantitative Systems Pharma-
cology Network now funded by the EPSRC aims to bring together
experimental and theoretical scientists in both academia and indus-
try. Within the QSP community it is clear that QSP is not just
aimed at developing single-use models, but that it is a central
and core component of the drug development pipeline. The real
worth of QSP is perhaps in integrating the multiple aspects of a
compound’s development, incorporating the fundamental disease
biology, pharmacokinetics and pharmacodynamics including toxicity
and clinical outcomes. QSP models could act as central knowledge
repositories, improving data communications between collaborating
teams. Such a radical pipeline reshuﬄe may be key to refreshing the
drug discovery paradigm.
It is heartening to note the recent positive trend in annual NTE
output. Partial responsibility may lie in the increased application of
pharmacometrics in NDA approvals [28] with 80–90% of drugs being
successful in the FDA review process [7, 12]. However, the fraction
of drugs that make it through clinical trials to the NDA stage is
only 12% which contributes to the substantial cost of pharmaceutical
R&D [12]. QSP can address the eﬃcacy and toxicity which causes
this attrition by exploring the pathological mechanisms underlying
the disease. The models provided by QSP can be used to document
a drug’s likelihood of approval which can inform decision making
throughout the preclinical and clinical stages. Therefore, instead
of resorting to post-mortem analysis, the early and preventative
incorporation of QSP modelling into the drug discovery process
can increase R&D eﬃciency by regularly evaluating a compound’s
viability.
Just as PK models already drove down costly attrition, QSP
models, as a predictive platform, may further reduce late-stage drug
failure in tomorrow’s drug discovery pipeline, the impact of which
can only be positive for industry and patients alike.
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